2023
Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer
Han J, Zakeri K, Raab G, Hesse J, Shamseddine A, Chen L, Yu Y, Kang J, McBride S, Riaz N, Tsai C, Gelblum D, Sherman E, Wong R, Michel L, Lee N. Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer. Head & Neck 2023, 45: 2207-2216. PMID: 37439286, PMCID: PMC10981461, DOI: 10.1002/hed.27456.Peer-Reviewed Original ResearchConceptsLocoregional recurrenceDistant metastasisOverall survivalHNSCC patientsConcurrent carboplatinDefinitive chemoradiationConsecutive HNSCC patientsDefinitive radiation therapyMedian radiation doseKaplan-Meier methodCumulative incidence functionFree survivalAdvanced headMedian ageMedian dosesNeck cancerAUC 1Radiation therapyCarboplatinPatientsChemoradiationPaclitaxelRadiation doseExcellent optionIncidence function
2022
Peer Review of Head and Neck Cancer Planning Target Volumes in Radiation Oncology
Hesse J, Zakeri K, Chen L, Yu Y, Kang J, Riaz N, Tsai C, McBride S, Gelblum D, Lee N. Peer Review of Head and Neck Cancer Planning Target Volumes in Radiation Oncology. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e472-e473. DOI: 10.1016/j.ijrobp.2022.07.1729.Peer-Reviewed Original ResearchStart of RTTarget volumeFurther workupNeck cancerTreatment planPositive findingsNeck radiation oncologistMinority of patientsOverall treatment planTreatment planningPlanning target volumeProspective peer reviewTumor board discussionMATERIAL/METHODSNeck cancer casesRadiation treatment plansFurther surgeryUnderwent biopsyAdditional surgeryAdditional workupOncology servicesSignificant changesCancer casesPatientsRadiation oncologistsPeer Review of Head and Neck Cancer Planning Target Volumes in Radiation Oncology
Hesse J, Chen L, Yu Y, Kang J, Riaz N, Tsai C, McBride S, Gelblum D, Zakeri K, Lee N. Peer Review of Head and Neck Cancer Planning Target Volumes in Radiation Oncology. Advances In Radiation Oncology 2022, 7: 100917. PMID: 35647395, PMCID: PMC9133360, DOI: 10.1016/j.adro.2022.100917.Peer-Reviewed Original ResearchStart of RTAdditional workupTarget volumeAdditional surgeryNeck cancerTreatment planPositive findingsNeck radiation oncologistMinority of patientsOverall treatment planTreatment planningPlanning target volumeProspective peer reviewTumor board discussionNeck cancer casesRadiation treatment plansUnderwent biopsyMedical oncologistsSignificant changesCancer casesAdditional consultationPatientsRadiation oncologistsRadiation therapy planningTreatment volume
2021
The effect of short radiation treatment breaks on chemo‐radiotherapy for oropharyngeal cancers
Rybkin A, Kang JJ, Lee A, Kitpanit S, Fan M, Mohamed N, Cartano O, Zakeri K, Gelblum D, Sherman E, Dunn L, Boyle J, Wong R, Chen L, Yu Y, McBride SM, Tsai CJ, Riaz N, Lee NY. The effect of short radiation treatment breaks on chemo‐radiotherapy for oropharyngeal cancers. Head & Neck 2021, 43: 3796-3809. PMID: 34585792, PMCID: PMC9414892, DOI: 10.1002/hed.26879.Peer-Reviewed Original ResearchConceptsRadiation treatment breaksOropharyngeal squamous cell carcinomaOverall treatment timeTreatment breaksClinical outcomesDefinitive concurrent chemoradiotherapySquamous cell carcinomaConcurrent chemoradiotherapyOPSCC patientsOropharyngeal cancerDisease failureCell carcinomaNeck cancerCancer recurrenceConsecutive cohortMultivariate analysisSignificant associationPatientsCancerFurther investigationProlongationDaysOutcomesNumerous studiesChemoradiotherapy
2020
The 3 Bs of cancer care amid the COVID‐19 pandemic crisis: “Be safe, be smart, be kind”—A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer
Kang JJ, Wong RJ, Sherman EJ, Rybkin A, McBride SM, Riaz N, Tsai CJ, Yu Y, Chen L, Zakeri K, Gelblum DY, Gillespie EF, Cohen MA, Cracchiolo JR, Ganly I, Patel S, Singh B, Boyle JO, Roman BR, Morris LG, Shaha AR, Dunn LA, Ho AL, Fetten JV, Shah JP, Pfister DG, Lee NY. The 3 Bs of cancer care amid the COVID‐19 pandemic crisis: “Be safe, be smart, be kind”—A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer. Cancer 2020, 126: 4092-4104. PMID: 32639615, PMCID: PMC7361524, DOI: 10.1002/cncr.33031.Peer-Reviewed Original ResearchConceptsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2High-volume cancer centerRespiratory syndrome coronavirus 2Coronavirus disease 2019 (COVID-19) pandemicSyndrome coronavirus 2Neck cancer treatmentDisease 2019 pandemicPersonal protective equipmentPublic health directivesEndoscopic evaluationNonsurgical treatmentCancer CenterCoronavirus 2Cancer careNeck cancerHNC treatmentOropharyngeal tractUse of radiationFeasibility dataMultidisciplinary conferenceCancer treatmentProtective equipmentRadiation oncologyMultidisciplinary approachBeyond reirradiation: Efficacy and safety of three or more courses of radiation for head and neck malignancies
Xu AJ, Luo L, Leeman JE, Romesser PB, Spielsinger D, Sabol C, Waldenberg T, Brinkman T, Riaz N, McBride S, Kang J, Lee N, Tsai CJ. Beyond reirradiation: Efficacy and safety of three or more courses of radiation for head and neck malignancies. Clinical And Translational Radiation Oncology 2020, 23: 30-34. PMID: 32382663, PMCID: PMC7200775, DOI: 10.1016/j.ctro.2020.04.009.Peer-Reviewed Original ResearchCourse of radiationMedian local recurrence-free survivalNeck regionLocal recurrence-free survivalGrade 5 toxicityMedian overall survivalRecurrence-free survivalSingle-institution databaseFree survivalOverall survivalSelect patientsSystemic therapyNeck malignanciesRecurrent headSignificant morbiditySubsequent therapyNeck cancerMulti-disciplinary teamGrade 3Institution's databasePatientsLocal controlReirradiationTreatment planMultiple coursesPredictors of Immunotherapy Response in Head and Neck Cancer: Per Lesion Analysis of a Prospective Randomized Trial with Nivolumab
Yu Y, Chen L, Riaz N, Tsai C, Kang J, Sherman E, Lee N, McBride S. Predictors of Immunotherapy Response in Head and Neck Cancer: Per Lesion Analysis of a Prospective Randomized Trial with Nivolumab. International Journal Of Radiation Oncology • Biology • Physics 2020, 106: 1131. DOI: 10.1016/j.ijrobp.2019.11.359.Peer-Reviewed Original ResearchLast-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers
Fan D, Kang JJ, Fan M, Wang H, Lee A, Yu Y, Chen L, Tsai C, McBride SM, Riaz N, Gelblum DY, Neal BP, Fetten J, Dunn LA, Michel LS, Boyle JO, Cohen MA, Roman BR, Ganly I, Singh B, Wong RJ, Sherman EJ, Lee NY. Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers. Oral Oncology 2020, 104: 104641. PMID: 32182548, PMCID: PMC8480112, DOI: 10.1016/j.oraloncology.2020.104641.Peer-Reviewed Original ResearchConceptsLocoregional progression-free survivalQuad Shot regimenOverall survivalPalliative responseRadiation therapyNeck cancerMedian locoregional progression-free survivalGrade 3 toxicity ratesOverall palliative response rateMedian overall survivalPalliative response ratePrior radiation therapyProgression-free survivalRadiation-related toxicityFree survivalPalliative therapyMedian ageLocal therapyPalliative optionSurvival improvementProton radiation therapyToxicity ratesTumor reductionIrradiated headLocal treatmentTemporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base
Kitpanit S, Lee A, Pitter KL, Fan D, Chow JCH, Neal B, Han Z, Fox P, Sine K, Mah D, Dunn LA, Sherman EJ, Michel L, Ganly I, Wong RJ, Boyle JO, Cohen MA, Singh B, Brennan CW, Gavrilovic IT, Hatzoglou V, O'Malley B, Zakeri K, Yu Y, Chen L, Gelblum DY, Kang JJ, McBride SM, Tsai CJ, Riaz N, Lee NY. Temporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base. International Journal Of Particle Therapy 2020, 6: 17-28. PMID: 32582816, PMCID: PMC7302730, DOI: 10.14338/ijpt-20-00014.1.Peer-Reviewed Original ResearchMagnetic resonance imagingRadiation-naïve patientsDose-volume parametersSkull baseNeck cancerTemporal lobeCutoff valueMaximum doseProton therapyAdverse Events v5.0Common Terminology CriteriaTemporal lobe necrosisNeck cancer patientsDose-volume factorsTerminology CriteriaMedian followBrain necrosisMedian timeClinical parametersCancer patientsMedical recordsGrade 3Necrosis rateField of radiationPatients
2019
Platinum‐based regimens versus cetuximab in definitive chemoradiation for human papillomavirus‐unrelated head and neck cancer
Beckham TH, Barney C, Healy E, Wolfe AR, Branstetter A, Yaney A, Riaz N, McBride SM, Tsai CJ, Kang J, Yu Y, Chen L, Sherman E, Dunn L, Pfister DG, Tan J, Rupert R, Bonomi M, Zhang Z, Lobaugh SM, Grecula JC, Mitchell DL, Wobb JL, Miller ED, Blakaj DM, Diavolitsis VM, Lee N, Bhatt AD. Platinum‐based regimens versus cetuximab in definitive chemoradiation for human papillomavirus‐unrelated head and neck cancer. International Journal Of Cancer 2019, 147: 107-115. PMID: 31609479, DOI: 10.1002/ijc.32736.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCetuximabChemoradiotherapyCisplatinFemaleHead and Neck NeoplasmsHumansMaleMiddle AgedNeoplasm StagingPapillomaviridaePapillomavirus InfectionsRandomized Controlled Trials as TopicSquamous Cell Carcinoma of Head and NeckSurvival RateConceptsLocoregional failureOverall survivalDistant metastasisReduced hazardMultivariable analysisKaplan-MeierHuman papillomavirus-unrelated headNeck squamous cell carcinomaPlatinum-based regimensSquamous cell carcinomaSuperior locoregional controlCumulative incidence functionDefinitive chemoradiationDefinitive radiotherapyLocoregional controlAdvanced headClinical characteristicsCumulative incidenceConcurrent cetuximabPropensity matchingYear OSCell carcinomaHuman papillomavirusNeck cancerProportional hazardsPredictors of Early Response to Immunotherapy in Head and Neck Cancer: A Secondary Clinical and Radiomic Analysis of a Prospective Randomized Trial with Nivolumab
Yu Y, Chen L, Riaz N, Kang J, Thor M, Veeraraghavan H, Apte A, Tsai C, Deasy J, Sherman E, Lee N, McBride S. Predictors of Early Response to Immunotherapy in Head and Neck Cancer: A Secondary Clinical and Radiomic Analysis of a Prospective Randomized Trial with Nivolumab. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s211. DOI: 10.1016/j.ijrobp.2019.06.286.Peer-Reviewed Original ResearchTiming of surgery and adjuvant radiation therapy for sinonasal malignancies: Effect of surgical approach
Xiao R, Joshi RR, Husain Q, Cracchiolo JR, Lee N, Tsai J, Yu Y, Chen L, Kang JJ, McBride S, Riaz N, Roman BR, Ganly I, Tabar V, Gray ST, Cohen MA. Timing of surgery and adjuvant radiation therapy for sinonasal malignancies: Effect of surgical approach. Head & Neck 2019, 41: 3551-3563. PMID: 31294897, PMCID: PMC6742559, DOI: 10.1002/hed.25873.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, Squamous CellCombined Modality TherapyDatabases, FactualDisease-Free SurvivalEndoscopyFemaleHumansKaplan-Meier EstimateLinear ModelsMaleMiddle AgedOtorhinolaryngologic Surgical ProceduresParanasal Sinus NeoplasmsPropensity ScoreRadiotherapy, AdjuvantRetrospective StudiesRisk AssessmentSurvival AnalysisTime FactorsConceptsSquamous cell carcinomaRadiation therapyEndoscopic surgeryPropensity score-matched analysisAdjuvant radiation therapyNational Cancer DatabasePostoperative radiation therapyKaplan-Meier methodTiming of surgeryDay of surgeryShorter postoperative timeMultivariable linear regressionOverall survivalPostoperative timeSinonasal malignanciesCell carcinomaSurgical approachNeck cancerCancer DatabaseParanasal sinusesSurvival advantageNasal cavitySurgeryPatientsExtended OSPredictors of early immunotherapy response in head and neck cancer: Per lesion analysis of a prospective randomized trial with nivolumab.
Yu Y, Chen L, Riaz N, Kang J, Tsai C, Sherman E, Lee N, McBride S. Predictors of early immunotherapy response in head and neck cancer: Per lesion analysis of a prospective randomized trial with nivolumab. Journal Of Clinical Oncology 2019, 37: 6041-6041. DOI: 10.1200/jco.2019.37.15_suppl.6041.Peer-Reviewed Original ResearchNon-irradiated lesionsOral cavity primariesRisk of progressionNeck cancerExact testLogistic regressionNeck primary sitePrimary tumor subsiteTrials of nivolumabPD-L1 statusLymph node metastasisMultivariate logistic regressionPredictors of responsePrimary tumor siteStereotactic body radiotherapyFisher's exact testElicit clinical responsesStable diseaseCheckpoint inhibitorsMetastatic headClinical responseFirst doseLiver metastasesMetastasis locationProgressive diseaseTrends and Disparities of Proton Therapy Use among Patients with Head and Neck Cancer: Analysis from the National Cancer Database (2005-14)
Lee A, Kang J, Yu Y, McBride S, Riaz N, Cohen M, Sherman E, Michel L, Lee N, Tsai CJ. Trends and Disparities of Proton Therapy Use among Patients with Head and Neck Cancer: Analysis from the National Cancer Database (2005-14). International Journal Of Particle Therapy 2019, 5: 1-10. PMID: 31773036, PMCID: PMC6871620, DOI: 10.14338/ijpt-19-00051.1.Peer-Reviewed Original ResearchNational Cancer DatabasePrimary disease siteMultivariable logistic regressionTherapy useNeck cancerRadiation therapyCancer DatabasePrimary siteDisease sitesNasal cavity/nasopharynxLogistic regressionInitial treatment courseNeck primary malignancyProton therapyCommon primary siteDistribution of patientsHousehold income quartileT4 diseaseMost patientsPrimary malignancyClinical factorsNonmetastatic headTreatment coursePrimary headOral cavity